CTC
MRTX

Central Trust Company’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Central Trust Company’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15
Closed -$882 – 1433
2023
Q4 		$882 Hold
15
– – ﹤0.01% 1330
2023
Q3 		$654 Buy
+15
New +$536 ﹤0.01% 1329
2022
Q1 		– Sell
-50
Closed -$7K – 1528
2021
Q4 		$7K Hold
50
– – ﹤0.01% 1108
2021
Q3 		$9K Hold
50
– – ﹤0.01% 1061
2021
Q2 		$8K Buy
+50
New +$8.03K ﹤0.01% 1054

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Central Trust Company's MRTX Position: Q1 2024 in Review

Central Trust Company sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 15 shares — an estimated $882 sold.

Central Trust Company first reported a position in MRTX in Q2 2021 and held it in 5 quarters. The position peaked at $9K in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Central Trust Company reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Central Trust Company sold 15 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $882.
  • Central Trust Company first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • Central Trust Company's Mirati Therapeutics, Inc. Common Stock position peaked at $9K in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Central Trust Company's 13F filing for Q1 2024, filed 24 Apr 2024.